Tag: Acerus Pharmaceuticals Corporation
December 11, 2018
Acerus Announces Results of Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) is today providing results of a Phase 1 clinical trial (the “trial”)...
November 26, 2018
Acerus Provides Update on Continuing Commercial and R&D Achievements for NATESTO®
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) is today providing an update on a number of significant operational and...
October 31, 2018
Acerus Announces Expansion of NATESTO® Agreement with medac and the Submission of NATESTO® Dossier in Europe
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced the signing of an amendment to its existing licensing and...
October 30, 2018